Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 13, 2020

SELL
$6.21 - $14.02 $150,505 - $339,788
-24,236 Reduced 2.5%
946,423 $12.9 Million
Q2 2019

Aug 13, 2019

BUY
$5.65 - $7.5 $5.48 Million - $7.28 Million
970,659 New
970,659 $5.82 Million

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track New Leaf Venture Partners, L.L.C. Portfolio

Follow New Leaf Venture Partners, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Leaf Venture Partners, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on New Leaf Venture Partners, L.L.C. with notifications on news.